PMID- 37215706
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230523
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 10
DP  - 2023
TI  - HAIC as a potential therapy for esophageal cancer patients with liver metastasis: 
      a retrospective cohort study.
PG  - 1143617
LID - 10.3389/fmed.2023.1143617 [doi]
LID - 1143617
AB  - METHODS: This was a single-arm historical cohort study of ESCC patients with 
      synchronous or heterochronous LM between December 2014 and July 2021 at the 
      Department of Gastrointestinal Oncology. The patients were treated with HAIC for 
      LM, and regular image assessments were performed according to the judgment of the 
      interventional physician. Liver progression-free survival (PFS), liver objective 
      response rate (ORR), liver disease control rate (DCR), overall survival (OS), 
      adverse events (AEs), treatment information, and basic characteristics were 
      observed retrospectively. RESULTS: Overall, a total of 33 patients were enrolled 
      in this study. All included patients received catheterized HAIC therapy, with a 
      median of three (ranging from 2 to 6) sessions. The treatment response of liver 
      metastatic lesions included partial response (PR) in 16 (48.5%) patients, stable 
      disease (SD) in 15 (45.5%) patients, and progressive disease (PD) in two (6.1%) 
      patients, for an ORR of 48.5% and a DCR of 93.9%. The median liver PFS was 4.8 
      months (95% confidence interval (CI): 3.0-6.6 months), and the median OS was 6.4 
      months (95% CI: 6.1-6.6 months). Patients who achieved PR at the liver metastasis 
      site after HAIC were more likely to have a longer OS than those who achieved SD 
      or PD. Grade 3 AEs occurred in 12 patients. The most common grade 3 AE was 
      nausea, occurring in 10 (30.0%) patients, followed by abdominal pain in three 
      (9.1%) patients. Only one patient showed grade 3 elevation of alanine 
      aminotransferase (ALT)/aspartate aminotransferase (AST), and one patient suffered 
      from grade 3 embolism syndrome AEs. Grade 4 adverse events, followed by abdominal 
      pain, occurred in one patient. CONCLUSION: Hepatic arterial infusion chemotherapy 
      might be an option as a regional therapy for ESCC patients with LM, as it is 
      acceptable and tolerable.
CI  - Copyright (c) 2023 Dong, Cao and Lu.
FAU - Dong, Fengxiao
AU  - Dong F
AD  - Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Key 
      Laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Peking University Cancer Hospital and Institute, Beijing, China.
FAU - Cao, Guang
AU  - Cao G
AD  - Department of Interventional Therapy, Peking University Cancer Hospital, Key 
      Laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Peking University Cancer Hospital and Institute, Beijing, China.
FAU - Lu, Zhihao
AU  - Lu Z
AD  - Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Key 
      Laboratory of Carcinogenesis and Translational Research (Ministry of Education), 
      Peking University Cancer Hospital and Institute, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20230505
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC10196257
OTO - NOTNLM
OT  - HAIC
OT  - esophagus squamous cell carcinoma
OT  - gastrointestinal tumor
OT  - liver metastasis
OT  - local therapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/05/22 19:11
MHDA- 2023/05/22 19:12
PMCR- 2023/05/05
CRDT- 2023/05/22 12:30
PHST- 2023/01/13 00:00 [received]
PHST- 2023/03/27 00:00 [accepted]
PHST- 2023/05/22 19:12 [medline]
PHST- 2023/05/22 19:11 [pubmed]
PHST- 2023/05/22 12:30 [entrez]
PHST- 2023/05/05 00:00 [pmc-release]
AID - 10.3389/fmed.2023.1143617 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2023 May 5;10:1143617. doi: 10.3389/fmed.2023.1143617. 
      eCollection 2023.